imatinib mesylate has been researched along with Hepatitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, H; Fukushima, T; Kobayashi, C; Nanmoku, T; Sakai, A; Satomi, K; Sumazaki, R; Suzuki, R; Tagawa, M | 1 |
| Kawano-Yamamoto, C; Kikuchi, S; Komatsu, N; Miyazato, A; Mori, M; Muroi, K; Nagai, T; Ozawa, K; Takahashi, S; Takatoku, M | 1 |
2 other study(ies) available for imatinib mesylate and Hepatitis
| Article | Year |
|---|---|
Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Child; Female; Hepatitis; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Pyrimidines | 2015 |
Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Female; Hepatitis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Piperazines; Prothrombin Time; Pyrimidines; Remission Induction; Seasons; Time Factors; Treatment Outcome | 2004 |